Clinical trialNCT01966107CompletedPhase 4Interventional

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

SponsorAstraZenecaEnrollment3,635COPDChronic Obstructive Pulmonary DiseaseModerate to Very Severe COPD

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kenneth R. Chapman, MD MSc FRCPC FACP FCCP
GSK-CIHR Research Chair in Respiratory Health Care Delivery,
Principal Investigator
clinicaltrials.gov ↗
Robert Wise, MD
Johns Hopkins Bayview Medical Center, Asthma and Allergy Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

468 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Research Site
Edmonton, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Kamloops, British Columbia, Canada
Research Site
Kelowna, British Columbia, Canada
Research Site
Langley, British Columbia, Canada
Research Site
Penticton, British Columbia, Canada
Research Site
West Vancouver, British Columbia, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
Bridgewater, Nova Scotia, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Ajax, Ontario, Canada
Research Site
Burlington, Ontario, Canada
Research Site
Cornwall, Ontario, Canada
Research Site
Dorchester, Ontario, Canada
Research Site
Greater Sudbury, Ontario, Canada
Research Site
Greater Sudbury, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
Thorold, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Waterloo, Ontario, Canada
Research Site
Windsor, Ontario, Canada
Research Site
Windsor, Ontario, Canada
Research Site
Longueuil, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Saint-Charles-Borromée, Quebec, Canada
Research Site
Saskatoon, Saskatchewan, Canada

United States

Research Site
Birmingham, Alabama, United States
Research Site
Birmingham, Alabama, United States
Research Site
Birmingham, Alabama, United States
Research Site
Birmingham, Alabama, United States
Research Site
Birmingham, Alabama, United States

428 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Oct 2013
Primary completion: 21 Sept 2017
Completion: 21 Sept 2017
Last update posted: 6 Dec 2018
Registered enrollment: 3,635
Registry id: NCT01966107

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.